| NBDF

New Approval Expands Indication for Recombinant VWD Therapy

Read more about New Approval Expands Indication for Recombinant VWD Therapy

FDA expands VONVENDI approval to include prophylaxis for adults with von Willebrand disease and pediatric on-demand use, advancing care across all VWD types.

Government Relations Update - August 2025

Read more about Government Relations Update - August 2025

NBDF advocates for bleeding disorders care and coverage—BDC 2025 highlights, federal policy updates, Medicaid privacy, insurance reforms, and state actions.

Spotlight on Be Biopharma, a Pathway to Cure’s Portfolio Company

Read more about Spotlight on Be Biopharma, a Pathway to Cure’s Portfolio Company

A New Class of Cellular Medicines: The First Engineered B Cell Medicine to Enter Clinical Trials for Hemophilia B

Subscribe to Subscribe to